CagriSema Didn't Hit Its 25% Target, But the REDEFINE 1 Data Still Matter — Here's Why

When Novo Nordisk first announced its ambition for CagriSema, the company set an unusually specific public benchmark: 25 percent average weight loss, a number that would have placed it ahead of every other obesity medication currently available or in late-stage development. When the full Phase 3 REDEFINE 1 results came out, and now with the drug's FDA application under active review, I think it is worth walking patients through both what the trial actually showed and why "falling short of a target" is a very different story from "failing."

CagriSema is a fixed-dose combination of cagrilintide, an amylin analog, and semaglutide, the same GLP-1 receptor agonist found in Wegovy and Ozempic, delivered together as a single once-weekly injection at 2.4 mg of each component. Amylin is a hormone released by the pancreas alongside insulin that helps regulate satiety and gastric emptying through mechanisms distinct from, but complementary to, GLP-1. The scientific rationale for combining the two was that hitting appetite regulation through two separate hormonal pathways simultaneously might produce weight loss greater than either drug alone — and the trial data broadly support that reasoning, even if the final number came in under the initial target.

REDEFINE 1 enrolled 3,417 adults with obesity or overweight plus at least one weight-related health condition, making it one of the largest Phase 3 obesity trials conducted to date. Over 68 weeks, participants receiving CagriSema lost an average of 22.7 percent of their body weight. For context, the trial also included separate comparison arms: cagrilintide alone produced 11.8 percent weight loss, semaglutide alone produced 16.1 percent, and placebo produced 2.3 percent. In other words, the combination outperformed either individual component by a wide margin, which is exactly the result you would want to see to justify combining two drugs rather than prescribing one. Importantly, 40.4 percent of individual participants did reach or exceed the original 25 percent target, even though the trial-wide average fell short of it — average results can understate what a meaningful subset of patients actually experience.

One detail worth flagging for patients considering this class of medication in the future: only 57.3 percent of participants in the treatment group reached the highest available dose by the end of the trial, meaning a substantial portion of the 22.7 percent average weight loss figure was achieved even among people who had not yet reached full-strength dosing. This raises a reasonable question of whether the true ceiling for CagriSema's effect, at full-dose, fully-titrated use, may be somewhat higher than the headline average suggests — something later analyses and real-world data will help clarify.

On safety, Novo Nordisk has reported a tolerability profile broadly consistent with other GLP-1-based therapies: mild-to-moderate gastrointestinal side effects, such as nausea and constipation, that tended to diminish over time as the body adjusted to treatment.

As for where things stand right now: Novo Nordisk submitted its new drug application to the FDA in December 2025, and a regulatory decision is anticipated sometime in the fourth quarter of 2026. As of this writing, CagriSema is not yet FDA-approved, and I want to be direct with patients about what that means practically — an FDA decision, even a positive one, is only the first of several steps (including manufacturing scale-up, insurance coverage negotiations, and pharmacy distribution) that typically stand between drug approval and a prescription actually reaching your local pharmacy.

My honest read for patients asking about CagriSema today: this is a legitimately promising addition to the obesity treatment landscape, with weight loss results that sit in a similar range to, and in this trial modestly below, what we have seen with tirzepatide in head-to-head comparisons reported elsewhere. The appeal of amylin-GLP-1 combination therapy is real, and I expect this general strategy — targeting multiple appetite-regulating hormones simultaneously — to be a defining feature of the next generation of obesity medications, including several others currently in earlier-phase trials. For now, if you are currently doing well on semaglutide or tirzepatide, there is no reason to wait for CagriSema; if you have not yet had success with available options, it is a drug worth asking your physician about tracking as it moves through the approval process.

Source: Phase 3 REDEFINE 1 trial (Novo Nordisk); FDA new drug application submitted December 2025, decision anticipated Q4 2026.